QHSLab Reports Revenue Growth to $728,685 but Incurred Net Loss of $103,906 in Q1 2026

QHSLab, Inc. reported its financial results for the first quarter of 2026, revealing a revenue increase to $728,685, up from $645,419 in the same period last year. The growth in revenue was primarily driven by a significant rise in Integrated Service Program (ISP) revenues, which surged by 130.5% to $374,501 compared to $162,502 in the first quarter of 2025. However, the company also noted a decrease in sales from its Allergy Diagnostic Kit and Immunotherapy Treatment segments, contributing to a slight decline in gross margin from 66.6% to 64.6%. The cost of revenues increased to $257,882 from $215,475, reflecting the higher costs associated with the ISP services.

In terms of profitability, QHSLab reported a net loss of $103,906 for the three months ended March 31, 2026, compared to a loss of $79,609 in the prior year. The increase in net loss was attributed to higher operating expenses, which rose to $565,183 from $441,983, driven by increased sales and marketing costs as the company invests in expanding its customer base and product offerings. General and administrative expenses also increased, reflecting the costs associated with operational growth. The company’s accumulated deficit reached $4,007,457 as of March 31, 2026.

Operationally, QHSLab's total current assets decreased to $619,058 from $883,009 at the end of 2025, primarily due to a reduction in cash and cash equivalents, which fell to $362,088 from $636,157. Current liabilities also decreased to $368,005 from $449,860, largely due to repayments of loans and a reduction in accounts payable. The company’s employee headcount and customer engagement metrics were not disclosed in the filing, but the management indicated a focus on increasing the number of primary care physicians (PCPs) utilizing their products and services.

Strategically, QHSLab continues to enhance its product offerings, particularly through its QHSLab platform, which provides clinical decision support and patient monitoring. The company aims to expand its market presence by introducing additional point-of-care diagnostics and treatments. Despite the challenges posed by its financial performance, management remains optimistic about future growth, emphasizing the importance of generating positive cash flow and exploring options for additional capital to support ongoing operations.

Looking ahead, QHSLab's management acknowledged the uncertainties surrounding its ability to continue as a going concern, given its history of losses and the need for ongoing financing. The company plans to focus on increasing revenues through its subscription model and expanding its service offerings to PCPs. However, they cautioned that access to funding may not be guaranteed, and the financial markets' conditions could significantly impact their operational capabilities and growth prospects.